<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00026104</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02423</org_study_id>
    <secondary_id>RTOG-PA-0020</secondary_id>
    <secondary_id>CDR0000068986</secondary_id>
    <secondary_id>U10CA021661</secondary_id>
    <nct_id>NCT00026104</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer</brief_title>
  <official_title>A Randomized Phase II Trial of Weekly Gemcitabine, Paclitaxel and External Irradiation (50.4 GY) Followed by the Farnesyl Transferase Inhibitor R115777 (NSC #702818) for Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Randomized phase II trial to compare the effectiveness of gemcitabine, paclitaxel, and&#xD;
      radiation therapy with or without tipifarnib in treating patients who have locally advanced&#xD;
      pancreatic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from&#xD;
      dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage&#xD;
      tumor cells. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary&#xD;
      for tumor cell growth. Combining chemotherapy and radiation therapy with tipifarnib may be an&#xD;
      effective treatment for pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Compare the 1-year survival rate in patients with locally advanced pancreatic cancer&#xD;
      treated with paclitaxel, gemcitabine, and radiotherapy with or without tipifarnib.&#xD;
&#xD;
      II. Determine the toxicity and loco-regional activity of this chemoradiotherapy regimen in&#xD;
      these patients.&#xD;
&#xD;
      III. Determine the feasibility and toxicity of prolonged administration of tipifarnib after&#xD;
      chemoradiotherapy in these patients.&#xD;
&#xD;
      IV. Determine whether tipifarnib administered after chemoradiotherapy can increase&#xD;
      progression-free and overall survival in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to weight&#xD;
      loss in the preceding 6 months (more than 10% vs 10% or less) and tumor dimension (at least 5&#xD;
      cm vs less than 5 cm). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      Arm I: Patients receive radiotherapy once daily, 5 days a week, for 5.5 weeks, beginning on&#xD;
      day 1. Patients also receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes on&#xD;
      days 1, 8, 15, 22, 29, and 36.&#xD;
&#xD;
      Arm II: Patients receive chemoradiotherapy as in arm I. Within 3-8 weeks after completion of&#xD;
      chemoradiotherapy, patients without disease progression receive oral tipifarnib twice daily&#xD;
      for 21 days.&#xD;
&#xD;
      Treatment continues every 28 days in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then&#xD;
      annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>Calculated along with associated 95% confidence intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of patients developing unacceptable toxicity defined as grade 3 or higher gastrointestinal or pulmonary toxicity and/or discontinuation of treatment</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Graded according to the CTCAE version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in overall survival between treatment regimens</measure>
    <time_frame>1 year</time_frame>
    <description>Estimated with a 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Calculated along with associated 95% confidence intervals.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Adenocarcinoma of the Pancreas</condition>
  <condition>Stage II Pancreatic Cancer</condition>
  <condition>Stage III Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (radiation therapy, paclitaxel, gemcitabine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive radiotherapy once daily, 5 days a week, for 5.5 weeks, beginning on day 1. Patients also receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes on days 1, 8, 15, 22, 29, and 36.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (radiation therapy, tipifarnib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive chemoradiotherapy as in arm I. Within 3-8 weeks after completion of chemoradiotherapy, patients without disease progression receive oral tipifarnib twice daily for 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (radiation therapy, paclitaxel, gemcitabine)</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>difluorodeoxycytidine hydrochloride</other_name>
    <other_name>gemcitabine</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (radiation therapy, paclitaxel, gemcitabine)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tipifarnib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II (radiation therapy, tipifarnib)</arm_group_label>
    <other_name>R115777</other_name>
    <other_name>Zarnestra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Undergo radiation therapy</description>
    <arm_group_label>Arm I (radiation therapy, paclitaxel, gemcitabine)</arm_group_label>
    <arm_group_label>Arm II (radiation therapy, tipifarnib)</arm_group_label>
    <other_name>irradiation</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>therapy, radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed unresectable, locally advanced adenocarcinoma of the pancreas&#xD;
&#xD;
               -  Residual disease after resection (R1 or R2, microscopic or macroscopic) allowed&#xD;
&#xD;
          -  No metastases in major viscera&#xD;
&#xD;
          -  No peritoneal seeding or ascites&#xD;
&#xD;
          -  Biliary or gastroduodenal obstruction must have drainage before starting study therapy&#xD;
&#xD;
          -  Radiographically assessable disease encompassable within a single irradiation field&#xD;
             (15 by 15 cm maximum)&#xD;
&#xD;
          -  Performance status - Zubrod 0-1&#xD;
&#xD;
          -  Granulocyte count at least 1,800/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  ALT less than 3 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine less than 3.0 mg/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past 2 years except non-melanoma skin cancer or&#xD;
             carcinoma in situ of the cervix, uterus, or bladder&#xD;
&#xD;
          -  No significant infection or other medical condition that would preclude study&#xD;
&#xD;
          -  No prior chemotherapy (including gemcitabine or paclitaxel) for pancreatic cancer&#xD;
&#xD;
          -  No other concurrent cytotoxic agents&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior radiotherapy to the planned field&#xD;
&#xD;
          -  No other concurrent radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tyvin Rich</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiation Therapy Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiation Therapy Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 9, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Tipifarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

